ImmunoGen, Inc Earning Date (IMGN)

USA |NASDAQ |USD

IMGN Earnings Date

|
Report Date Period Ending EPS Forecast Last Quarter's EPS Last Year's EPS
Jul 28, 2022 Jun 2022 - - $-0.15
Report Date Period Ending Revenue Forecast Last Quarter’s Revenue Last Year’s Revenue
Jul 28, 2022 Jun 2022 - - $16.95M

Immunogen, Inc's next earnings date is Thursday, Jul 28, 2022 for the fiscal quarter ending Jun 2022.

IMGN Earnings Date & History Chart

IMGN Earnings & Revenue Forecast

IMGN Earnings Forecast

|
Period End # of Analysts EPS Forecast Low EPS Forecast High EPS Forecast
Period End # of Analysts EPS Forecast Low EPS Forecast High EPS Forecast
Dec 2022 10 $-0.88 $-1.36 $-0.64

IMGN Earnings Revision Trend

|
Period End Up/Down 1M 1M Trend 2M Trend 3M Trend
Period End Up/Down 1M 1M Trend 2M Trend 3M Trend
Dec 2022 2 / 7 $-0.80 $-0.78 $-0.82

IMGN Revenue Forecast

|
Period End # of Analysts Revenue Forecast Low Revenue Forecast High Revenue Forecast
Period End # of Analysts EPS Forecast Low EPS Forecast High EPS Forecast
Dec 2022 10 $56.49M $30.30M $121.00M

IMGN Earnings Date & Revenue History

IMGN Earnings History

|
Show More
Show More

IMGN Revenue History

|
Show More
Show More

Immunogen, Inc Next Earnings Date & Report

IMGN Next Earnings Date & Report Preview: Jun 2022 (FQ)

IMGN's next earnings date is Thursday, Jul 28, 2022 for the fiscal quarter ending Jun 30, 2022.

Immunogen, Inc Previous Earnings Dates & Reports

IMGN Previous Earnings Date & Report Recap: Mar 2022 (FQ)

Immunogen, Inc's previous earnings date was May 9, 2022 for its fiscal quarter ended Mar 31, 2022.

IMGN Previous Earnings Date & Report Recap: Dec 2021 (FY)

Immunogen, Inc's previous annual earnings date was Feb 25, 2022 for its fiscal year ended Dec 31, 2021.

IMGN's earnings per share (EPS) was $-0.67, beating the consensus analysts forecast of $-0.68 by -1.47% , and lower than the previous year's EPS (Dec 2020) by 139.29%.

Revenues were $69.86M, better than the forecast of $67.54M by 3.43%, and down by -47.20% from previous year's revenue.

The company reported a net income of $-139.30M.

Immunogen, Inc reported a free cash flow of $-170.85M for its fiscal year, compared to $-79.54M a year ago.

The company ended the fiscal year with $18.78M in total debt, a decrease of -21.39% compared to the previous year.